Q-omics provides the consensus-scored GRAMD2B profile across patient tissues and cancer cell-line models. GRAMD2B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GRAMD2B is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, GRAMD2B RNA expression shows 18,973 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where GRAMD2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRAMD2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRAMD2B survival associations across molecular data types. GRAMD2B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRAMD2B RNA expression–survival associations across cancer types. High GRAMD2B expression shows unfavorable associations in STAD, MESO and PAAD, but favorable associations in KIRC, BLCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GRAMD2B RNA expression.
This table summarizes GRAMD2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GRAMD2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRAMD2B shows lower tumor expression in COAD, UCEC, BRCA, KICH and HNSC and higher tumor expression in LUAD. The COAD box plot shows higher GRAMD2B RNA expression in normal versus tumor tissue (log2 FC = −1.635, t-test p < 0.001).
This table shows molecular features associated with GRAMD2B in patient tissues and cancer cell lines. In patient samples, GRAMD2B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, GRAMD2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
